Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Pines Care Research Center LLC

Neither a doctor nor a teaching hospital

Research payments

$25,508,142

878 payments

Through program year 2025, Pines Care Research Center LLC is reported as receiving $25,508,142 in research payments, across 878 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,468,929 91
2024 Research $3,176,946 269
2023 Research $6,241,718 126
2022 Research $8,386,505 89
2021 Research $5,080,455 43
2020 Research $571,655 56
2019 Research $581,935 204

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $15,118,243 211 payments
  2. GlaxoSmithKline, LLC. $3,395,005 69 payments
  3. Sanofi US Services Inc. $2,257,624 89 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,533,403 3 payments
  5. Chiesi USA, Inc. $1,281,885 248 payments
  6. Eli Lilly and Company $870,805 5 payments
  7. Teva Pharmaceuticals USA, Inc. $518,171 48 payments
  8. Moderna TX, Inc. $232,727 17 payments
  9. Akebia Therapeutics Inc $221,667 177 payments
  10. Ferring International Pharmascience Center US $45,548 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $13,300,487 51 payments
  2. A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study $2,696,962 28 payments
  3. Phase II dose finding PoCC in CKD $1,405,629 2 payments
  4. Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $750,899 26 payments
  5. A Phase I/II Observer-Blind, Randomized, Multi-Center Trial to Evaluat $698,043 41 payments
  6. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $612,243 4 payments
  7. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma $589,780 12 payments
  8. A Phase 3 Randomized Observerblinded Study to Evaluate the Immunogenicity Safety and Tolerability of 2 Doses Compared to 3 Doses of Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $576,350 39 payments
  9. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $528,909 82 payments
  10. A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma $517,966 47 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record